Ovid Therapeutics names new CFO and CBO in leadership reshuffle
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
July 8, 2026 7:00 AM EDTKevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovids financial operations, following Jeffrey Ronas transition to an advisory roleEliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric... More
